Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px
Collaboration › Details

Roche–Exscientia: drug discovery software, 201901– collab up to CHF67m + royalties using Centaur Chemist to design drug candidates

 

Period Period 2019-01-07
Organisations Partner, 1st Roche (Group)
  Partner, 2nd Exscientia Ltd. (ex scientia)
  Group Exscientia (Group)
Products Product Centaur Chemist™ AI-based drug discovery platform
  Product 2 drug discovery
     

Exscientia Ltd.. (1/7/19). "Press Release: Exscientia Initiates Sixth AI Drug Discovery Partnership".

EXSCIENTIA TO RECEIVE UP TO CHF 67 MILLION IN UPFRONT PAYMENTS, RESEARCH SUPPORT AND MILESTONE PAYMENTS IN DISCOVERY COLLABORATION WITH ROCHE


Exscientia – the world-leading Artificial Intelligence (AI)-driven drug discovery company - is pleased to announce a drug discovery collaboration with Roche.

Exscientia will apply its cutting-edge, Centaur Chemist™, AI drug discovery platform to design pre-clinical drug candidates for Roche. Roche has the exclusive rights to develop and market the drug candidates resulting from the collaboration.

Exscientia receives upfront and research funding as well as pre-clinical, development and commercial milestone payments. Together, the combined financial reward is worth up to CHF 67 million to Exscientia, plus tiered royalties on the annual net sales of any products resulting from the collaboration. No further financial details are disclosed.

Andrew Hopkins, CEO of Exscientia, said: "The application of AI into early stage drug discovery has the potential to offer transformational benefits in terms of productivity and quality to the generation of new medicines. Increasingly, we are seeing in our own pipeline projects and with our ongoing collaborations, the success of our AI platform in drug discovery. This new partnership with Roche demonstrates the value of our AI-driven platform and its potential to deliver high value assets. We are very pleased to begin this exciting project with such a respected partner.”

Ends


Notes for editors


About Exscientia

Exscientia is at the forefront of Artificial Intelligence (AI)-driven drug discovery and design. By fusing the power of AI with the discovery experience of seasoned drug hunters, Exscientia is the first company to automate drug design, surpassing conventional approaches.

Exscientia’s innovative Centaur Chemist™ platform enables breakthrough productivity gains as well as new approaches to improve drug efficacy. Novel compounds are automatically designed and prioritised for synthesis by its AI systems, which rapidly evolve compounds towards the desired candidate criteria for clinical development.

Exscientia systems learn from both existing data resources and experimental data from each design cycle. The principle is similar to how a human would learn, but the AI process is far more effective at identifying and assimilating multiple subtle and complex trends to balance potency, selectivity and pharmacokinetic criteria.

As a result, the AI-driven process is more likely to achieve the end goal and to do this more rapidly and efficiently than traditional human endeavour.

Exscientia is collaborating with several leading pharmaceutical and life sciences companies, including GSK, Sanofi and Evotec.

Exscientia has its headquarters in Oxford, UK with offices in the UK, USA and Japan. For more information visit www.exscientia.co.uk or follow us on Twitter @exscientialtd


Media enquiries: Citigate Dewe Rogerson
Mark Swallow / Pip Batty / Sylvie Berrebi: exscientia@citigatedewerogerson.com
+44 207 638 9571

Mark Swindells - Chief Operating Officer: contact@exscientia.co.uk

   
Record changed: 2019-04-22

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 600x80px

More documents for Roche (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x112px




» top